Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-07-25
DOI
10.1093/eurheartj/ehaa649
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
- (2020) Vera A. Bittner et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
- (2020) Gregory G. Schwartz et al. CIRCULATION
- From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
- (2020) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
- (2020) Gerald F. Watts et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Modeling marginal features in studies of recurrent events in the presence of a terminal event
- (2019) Per Kragh Andersen et al. LIFETIME DATA ANALYSIS
- Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes
- (2019) Claudia Lamina et al. JAMA Cardiology
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
- (2018) Stephen Burgess et al. JAMA Cardiology
- Alirocumab Reduces Fatal and Nonfatal Cardiovascular Events
- (2018) Michael Szarek et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- ‘LDL-C’ = LDL-C + Lp(a)-C
- (2015) Calvin Yeang et al. CURRENT OPINION IN LIPIDOLOGY
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Lipoprotein(a)-cholesterol: A significant component of serum cholesterol
- (2011) Kiyoko Kinpara et al. CLINICA CHIMICA ACTA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started